### **Mitochondrial Disorders Clinical Impact of Result**

| Patient:            |   | [Patient name prefilled]                           |  |
|---------------------|---|--|--|
| Treating clinician: |   | [Clinician name prefilled]                         |  |
| Genomic t           | testing result:   |  |  |
| Result:             |   | [Result prefilled: positive, negative or VOUS]     |  |
| Pathogeni           | c/likely pathogenic genes:  | [Gene(s) prefilled]                                |  |
| SECTION I           | Changes in patient management arising for   | rom test result                                    |  |
| Please tick         | call relevant changes in patient manageme   | nt arising from the test result (whether positive, |  |
| negative o          | or VOUS).   |  |  |
| 1. Chang            | ge in diagnostic investigations   |  |  |
|                     | additional investigation initiated  |  |  |
|                     | unnecessary investigation cancelled or pre  | evented  |  |
| 2. Chang            | ge in pharmaceutical and other treatments   |  |  |
| ☐ Change            |   | (whether treatment started or unnecessary          |  |
|                     | specific treatment started  |  |  |
|                     | unnecessary specific treatment stopped o  | r not initiated                                    |  |
| ☐ Change            | e in nonspecific treatment for underlying ca  | use  |  |
|                     | nonspecific treatment started   |  |  |
|                     | unnecessary nonspecific treatment stoppe  | ed or not initiated                                |  |
|                     | ☐ Change in treatment for other aspects of the condition (e.g. movement disorder, gastrointestinal symptoms, other neurological symptoms, other organ problems) |  |  |
|                     | treatment for other aspects of the conditi  | on started   |  |
| П                   | unnecessary treatment for other aspects of  | of the condition stopped or not initiated          |  |

| 3. Change in other clinical management   |
|--|
| ☐ Change in screening for comorbidities  |
| $\square$ screening for comorbidities initiated  |
| $\square$ screening for comorbidities cancelled  |
| ☐ Change in referral to subspecialist  |
| $\square$ subspecialist referral initiated   |
| $\square$ subspecialist referral no longer required  |
| ☐ Change in overall direction of care  |
| $\square$ patient has been redirected towards palliation as a result of testing  |
| $\square$ previous decision to palliation has been reversed  |
|  |
| SECTION II Overall impact of test result   |
| How do you rate the clinical utility of genomic testing, in terms of changing process of management, for this patient? |
| □Not useful  |
| □Neutral   |
| □Useful  |
| □Very useful   |
| How do you rate the clinical utility of genomic testing, in terms of improving health outcomes, for this patient?      |
| □ Not useful   |
| □Neutral   |
| □Useful  |
| □Very useful   |

\_\_\_\_\_

Please specify the details on change in patient management arising from the test result that you selected in the previous section [Note: Only the pre-selected aspects of change will pop out; Clinicians will have chance to re-select or de-select the relevant fields]

#### SECTION I Changes in patient management arising from test result (either positive, negative or VOUS)

#### 1. How did test result change diagnostic investigations for aetiology?

#### Additional investigation(s) ordered to clarify the diagnosis

Please specify the additional investigation(s) ordered

| □Specific biochemistry:  |  |
|--|--|
| Name of the test(s)  |  |
| [+] add new field if required  |  |
| □MRI/MRS   |  |
| ☐ Biopsies/histology: ☐ Nerve biopsy ☐ Muscle biopsy ☐ Liver biopsy ☐ Others |  |
| ☐MRC enzymology  |  |
| ☐ Molecular genetic testing  |  |
| Name of the test(s)  |  |
| [+] add new field if required  |  |

#### Unnecessary investigations cancelled or prevented

Please specify the investigations cancelled or prevented

| □Specific biochemistry:   |
|---|
| Name of the test(s)   |
| [+] add new field if required   |
| □MRI/MRS  |
| ☐Biopsies/histology: ☐Nerve biopsy ☐Muscle biopsy ☐Liver biopsy ☐Others |
| ☐MRC enzymology   |
| ☐ Molecular genetic testing   |
| Name of the test(s)   |
| [+] add new field if required   |
|   |

| 2. | How did test | result change | pharmaceutical | l and other | treatments? |
|----|--------------|---------------|----------------|-------------|-------------|
|----|--------------|---------------|----------------|-------------|-------------|

## 2.1 Allow specific treatment for underlying cause Specific treatment started as a result of testing Please specify the treatment(s) initiated Name of treatment: [+] add new field if required Unnecessary specific treatment stopped or not initiated as a result of the testing Please specify the treatment(s) stopped Name of treatment: [+] add new field if required 2.2 Allow nonspecific treatment for underlying cause Nonspecific treatment started as a result of testing Please specify the treatment(s) initiated Name of treatment: [+] add new field if required

Unnecessary nonspecific treatment stopped or not initiated as a result of testing

Please specify the treatment(s) stopped

| Name of treatment:            | - |
|-------------------------------|---|
| [+] add new field if required |   |

# 2.3 <u>Change in treatment for other aspects of the condition (eg. movement disorder, gastrointestinal symptoms, other neurological symptoms, other organ problems)</u>

| Treatment for other aspects of the condition started   |
|--|
| Aspect of condition 1  |
| Please specify the treatment(s) initiated  |
| Name of treatment:   |
| [+] add new field if required  |
| [+] Add additional aspect of condition   |
| Treatment for other aspects of the condition stopped   |
| Aspect of condition 1  |
| Please specify the treatment(s) stopped  |
| Name of treatment:   |
| [+] add new field if required  |
| [+] Add additional aspect of condition   |
|  |
|  |
| 3. How did test result change other clinical management?   |
| <ul><li>3. How did test result change other clinical management?</li><li>3.1 Change in screening for comorbidities</li></ul>   |
|  |
| 3.1 Change in screening for comorbidities  |
| 3.1 Change in screening for comorbidities  Screening for comorbidities has been initiated  |
| 3.1 Change in screening for comorbidities  Screening for comorbidities has been initiated  Comorbidity 1   |
| 3.1 Change in screening for comorbidities  Screening for comorbidities has been initiated  Comorbidity 1  Please specify the screening initiated   |
| 3.1 Change in screening for comorbidities  Screening for comorbidities has been initiated  Comorbidity 1  Please specify the screening initiated  Screening test:  |
| 3.1 Change in screening for comorbidities  Screening for comorbidities has been initiated  Comorbidity 1  Please specify the screening initiated  Screening test:  Frequency:                              |
| 3.1 Change in screening for comorbidities  Screening for comorbidities has been initiated  Comorbidity 1  Please specify the screening initiated  Screening test:  Frequency:  Duration (number of years): |

| Please specify the screening cancelled   |
|--|
| Screening test:  |
| Frequency:   |
| Duration (number of years):  |
| [+] Add additional comorbidity   |
|  |
| 3.2 <u>Change in referral to subspecialist</u>                                 |
| Subspecialist referral has been initiated                                      |
| Please specify the subspecialty referred to and the frequency of visits        |
| Subspecialty:  |
| Number of visit(s) planned:  |
| ☐ One appointment  |
| ☐ Ongoing involvement of subspecialty planned                                  |
| If ongoing visits planned, please specify:                                     |
| Frequency of visits per year:  |
| Planned duration of surveillance/treatment (number of years):                  |
| [+] add additional subspecialty if required                                    |
| Prior subspecialist service is no longer required?                             |
| Please specify the subspecialty and the previously planned frequency of visits |
| Subspecialty:  |
| Number of visit(s) planned:  |
| ☐ One appointment  |
| $\square$ Ongoing involvement of subspecialty planned                          |
| If ongoing visits planned, please specify:                                     |
| Frequency of visits per year:  |
| Planned duration of surveillance/treatment (number of years):                  |

[+] add additional subspecialty if required

#### 3.3 Change in the overall direction of care

| Patient has been redirected towards palliation as a result of testing                                    |  |  |  |  |
|--|--|--|--|--|
| Comments   |  |  |  |  |
| Previous decision to palliation has been reversed  |  |  |  |  |
| Comments   |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| SECTION II Overall impact of test result   |  |  |  |  |
| [Note: Clinicians will have chance to review their answers and make changes if necessary.]               |  |  |  |  |
| How do you rate the clinical utility of genomic testing, in terms of changing process of management, for |  |  |  |  |
| this patient?  |  |  |  |  |
| □ Not useful   |  |  |  |  |
| □Neutral   |  |  |  |  |
| □Useful  |  |  |  |  |
| □Very useful   |  |  |  |  |
|  |  |  |  |  |
| How do you rate the clinical utility of genomic testing, in terms of improving health outcomes, for this |  |  |  |  |
| patient?   |  |  |  |  |
| □ Not useful   |  |  |  |  |
| □Neutral   |  |  |  |  |
| □Useful  |  |  |  |  |
| □Very useful   |  |  |  |  |